Ovulation Induction and Fertility Treatments

First-Line Ovulation Induction Agents

The American Society for Reproductive Medicine recommends clomiphene citrate 50-150 mg/day for 5 days as the first-line medication for anovulatory women with polycystic ovary syndrome (PCOS), inducing ovulation in approximately 70% of patients and achieving pregnancy rates of 44% within three treatment cycles 1
For women with PCOS or oligo-ovulation, starting with clomiphene citrate 50 mg daily for 5 days is recommended, with the option to increase to 100-150 mg if no ovulation occurs in the first cycle, and continuing for 3-6 ovulatory cycles before changing strategy 1

IUI with ovarian stimulation improves pregnancy rates in couples with unexplained infertility or mild male factor, with ovarian stimulation for IUI typically using clomiphene citrate or gonadotropins 1
IUI success is limited when total motile sperm count is <5 million after processing, and consideration should be given to proceeding directly to IVF/ICSI in these cases 2

Controlled ovarian stimulation with gonadotropins is the standard approach for fertility preservation before gonadotoxic treatments, with the option to add tamoxifen or letrozole to stimulation protocols in breast cancer patients to reduce estradiol exposure 3, 4
Letrozole or tamoxifen combined with gonadotropins achieves adequate oocyte yield with lower estradiol levels compared to standard protocols 4

GnRH agonists during chemotherapy do not reliably preserve fertility, with conflicting trial results showing some studies with higher menstrual recovery rates but no consistent increase in pregnancy rates 4
Testosterone therapy is absolutely contraindicated in women seeking fertility, as it suppresses ovulation 2